If you receive a denial letter from your insurer, seek legal advice before appealing the decision, says a leading disability ...

SINGAPORE, April 28, 2025 /EINPresswire / -- Singapore-based AscenZion Neuromodulation Co announced the publication of a significant paper on the 'Effect of transcranial pulsed current stimulation on ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich's ataxia in ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

(David Duprey / AP) A team of researchers at UT Southwestern Medical Center is aiming to find treatments for diseases of the cerebellum, a fist-sized structure in the back of the brain that helps ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Falls are the leading cause of injury-related death among seniors in the United States. Johns Hopkins researcher Kathleen ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market ...

Peter Gratton, M.A.P.P., Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, risk management, and public policy. Peter began covering markets at ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its Skyclarys (omaveloxolone) to treat Friedreich’s ataxia in ...

As with all products, we will keep its safety under close review. The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 April, approved omaveloxolone (Skyclarys), the first ...